Navigation Links
ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
Date:1/26/2011

ChemR23 and interrupt the early steps associated with the development of psoriatic dermal inflammation and other inflammatory diseases.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN (now designated GSK1605786, also known as GSK'786), a specific CCR9 antagonist, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development. Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus and associated complications; CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR antagonist, that completed Phase I clinical development and is anticipated to enter Phase II clinical trials in 2011; and CCX832, a ChemR23 antagonist in a Phase I clinical trial. ChemoCentryx also has several programs in advanced preclinical development. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.

Certain statements in this pres
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
3. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
4. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
5. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
6. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
9. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
10. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
11. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Surgeons at The Children,s Hospital of ... report the first successful use of a SynCardia temporary ... with failing Fontan circulation to bridge him to a ... old, the patient received a Fontan circulation procedure to ... "The Fontan operation is the final planned palliative operation ...
(Date:9/16/2014)... Va. , Sept. 16, 2014 ... Medical Directors Institute has simultaneously released the NAMCP ... NAMCP Medical Diagnostics Dossier Template © , which ... template formats for either medical devices or diagnostics ... aspects of each of these technology types (instead ...
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
Breaking Medicine Technology:13-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3NAMCP Medical Directors Institute releases NAMCP Medical Technologies and Diagnostics Dossier Templates to provide model approach for medical devices or diagnostics 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5
... The Netherlands, July 16 Neurofeedback - also,called EEG ... activity in order to,normalize Brain function and treat psychiatric ... 10 years, however the question,whether this treatment should be ... a study will be published in the scientific,journal ,EEG ...
... , , BOSTON and ... IIb multinational study(1) with edoxaban(2) - an investigational oral Factor ... atrial fibrillation (AF) receiving edoxaban once daily (QD) experienced fewer ... The analysis finds that bleeding associated with edoxaban is most ...
Cached Medicine Technology:New Research Shows: Neurofeedback is an 'Evidence-Based' Treatment for ADHD 2Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 2Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 3Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 4Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 5
(Date:9/16/2014)... Today, Top10BestSEOHosting.com compares many ... USA and announces that HostMonster, Arvixe and ... Windows web hosting companies in the market. ... high quality WordPress hosting (including VPS and ... HostMonster provides outstanding customer support and a ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Not all ... they take care to make sure all their patients ... For some, this may include the newly-introduced online therapy. ... program which gives patients the opportunity to seek treatment ... can provide medical and clinical care at a distance. ...
(Date:9/16/2014)... Aspen Advisors, a U.S.-based healthcare IT consulting firm, ... high morale and collaborative culture in the ... Work For 2014.” Consulting magazine publishes the popular ... participating across all major industries, representing more than 350 ... firms were ranked in six categories - firm culture, ...
(Date:9/16/2014)... may one day be able to predict when and ... sexual functioning, thanks in part to new findings that ... American Society for Radiation Oncology,s 56th Annual Meeting on ... more than 17,000 surveys completed by men diagnosed with ... and sexual symptoms changed following each type of treatment, ...
(Date:9/16/2014)... September 16, 2014 Who:, The Pulmonary ... Medical Campus and Children’s Hospital Colorado are ... the country’s leading pulmonary hypertension association that works to find ... disease of the lungs that affects the functioning of the ... mean survivability is only 2.8 years. , What:, Colorado ...
Breaking Medicine News(10 mins):Health News:Best Windows Web Hosting Suppliers Recommended By SEO Hosting Review Site Top10BestSEOHosting.com 2Health News:Millennium Treatment Group Now Offers Online Therapy 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 2Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2
... Insurance Convention Expected to Draw ... Protestors to San Francisco,Delgadillo to Discuss Legal Efforts to Crack Down ... and Unfair Business Acts and Practices" of Insurers, SAN ... of,protest against health insurance corporations, Los Angeles City Attorney,Rocky Delgadillo will ...
... the team that made the discovery, Professor Christopher Rowe ... and treatment presents medical practitioners with the best opportunity ... is at an experimental stage, this work places Australia ... Rowe says. , A 2004 Access Economics report calculated ...
... marks, get set go to lane 1? , ... connection between loud sounds and reaction time are reporting findings ... the upcoming Olympics. , Led by Dave Collins, professor ... hypothesized that the loud starter,s pistol at the Olympic Games ...
... Introduces ,The Insight, First ,Webisode, Featuring Guest, Hosts, Live Call-ins, ... ... Dealing With Change, BOCA RATON, Fla., ... Florida,s first weekly webisode -- a,transformational show called "The Insight" ...
... SAN CARLOS, Calif., June 18 Nuvelo, Inc.,(Nasdaq: ... the company,s chairman,and chief executive officer, will present at ... 2008, at 1:30 p.m. ET in New,York City., ... available online via,the Investor Relations portion of Nuvelo,s website ...
... ARAY ), a global leader in the field ... officer, Euan S.,Thomson, Ph.D., is scheduled to present at ... 10:15 a.m. EDT (7:15 a.m. PDT)., A live ... the,investor relations page of the Company,s Web site at, ...
Cached Medicine News:Health News:L.A. City Attorney Rocky Delgadillo, Patient Activists to Unveil New Television Ad Targeting Health Insurers 2Health News:L.A. City Attorney Rocky Delgadillo, Patient Activists to Unveil New Television Ad Targeting Health Insurers 3Health News:Advance towards early Alzheimer's diagnosis 2Health News:Sprinters closest to starter pistol have advantage over those farther away, says study 2Health News:A South Florida Premiere 2Health News:Accuray Incorporated's CEO to Speak at Jefferies Second Annual Healthcare Conference 2
... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
... 96 is a compact and self-contained multichannel ... tip manifold can be used in a ... in the optional active wash system. ... and adds safety. Optional ...
... for low volumes. Dispenses volumes down to ... Fast throughput of less than 30 seconds ... features an intuitive user interface that provides ... dispense liquids and suspensions, beads, or cells, ...
... Personal Pipettor is a cost-effective ... pipetting needs, from reagent additions ... more. Systems are available in ... using either fixed or disposable ...
Medicine Products: